{"entity":{"id":"nct06296706","kind":"trial","name":"A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer","aka":[],"tldr":"A phase 3 trial of Docetaxel in gastric & gastro-oesophageal junction cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.","summary":"A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer is a phase 3 interventional study registered as NCT06296706 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 630 participants planned, started 2024-02-27 and due to reach its primary completion in 2026-06-01. Interventions recorded: Docetaxel for injection (Albumin-bound) and Taxotere (docetaxel).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06296706","url":"https://clinicaltrials.gov/study/NCT06296706"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["docetaxel"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06296706","phase":"3","setting":"A Multicenter, Randomized, Controlled Phase III Clinical Study of Docetaxel for Injection (Albumin-bound) Versus Taxotere in Gastric Cancer","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","enrolled":630,"outcomes":[]},"route":"/trials/nct06296706/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}